Can ctDNA Measurements Predict DLBCL Outcomes?


A study shows pretreatment ctDNA levels and molecular responses are independently prognostic of outcomes in lymphomas.

Pretreatment levels of circulating tumor DNA (ctDNA) and molecular responses to therapy were independently prognostic of outcomes in patients with aggressive lymphoma, including diffuse large B-cell lymphoma (DLBCL), according to the results of a study published in The Journal of Clinical Oncology.

“The identification of patients at exceptionally high-risk (i.e., interim PET/CT positive and not achieving early molecular response/major molecular response) could provide an opportunity for early intervention with alternative treatments, including autologous bone marrow transplantation or chimeric antigen receptor T cells,” wrote David M. Kurtz, MD, of Stanford University, and colleagues. “The identification of this highest-risk group could improve risk-adapted approaches that have previously failed to improve outcome.”

According to the study, there are no existing methods for consistently predicting which patients with DLBCL will experience treatment failure for their disease. In this study, Kurtz and colleagues studied the dynamics of ctDNA in 217 patients treated for lymphoma at six centers.

Prior to undergoing therapy, ctDNA was detectable in almost all of the involved patients (98%), and was prognostic for patients undergoing front-line or salvage therapy.

The researchers used a discovery cohort to characterize early ctDNA during therapy to define response-associated thresholds. In this set, they found that ctDNA levels changed rapidly with a 2-log decrease after one cycle-indicating early molecular response-and a 2.5-log decrease after two cycles-indicating major molecular response and stratifying outcomes.

Next, the researchers assessed these thresholds in two independent validation sets. In the first set, those patients that received frontline therapy after achieving early molecular response (EMR) or major molecular response (MMR) had improved event-free survival at 24 months (EMR: 83% vs 50%; P = .0015; MMR: 82% vs 46%; P < .001). Achievement of early molecular response was also predictive of better event-free survival in those patients receiving salvage therapy (100% vs 13%; P < .011).

The prognostic value of achieving early and major molecular response was also confirmed in the second validation set. Prognostic value for overall survival was only found in one of the two validation sets, the researchers noted.

“Interestingly, the prognostic value of molecular response was independent of established factors, in multivariable analyses, both molecular response and interim PET/CT remained independently prognostic for survival,” the researchers wrote. “Moreover, the combination of molecular response and interim PET/CT response was able to robustly stratify event-free survival and overall survival.”

In order for widespread use in the clinic, the researchers noted that ctDNA assays will need to be standardized.

“These approaches may allow novel clinical trial designs, with wide applicability to patients with DLBCL and potentially other lymphomas,” the researchers wrote.

Recent Videos
The approval for epcoritamab in patients with R/R follicular lymphoma was supported by encouraging efficacy findings from the phase 1/2 EPCORE NHL-1 trial.
This series features 2 KOLs.
This series features 2 KOLs.
relapsed or refractory mantle cell lymphoma, glofitamab, Obinutuzumab, phase 1/2 study, NCT03075696, Tycel J. Phillips, MD
This series features 2 KOLs.
This series features 2 KOLs.
Future meetings may address how immunotherapy, bispecific agents, and CAR T-cell therapies can further impact the AML treatment paradigm.
Treatment with revumenib appeared to demonstrate efficacy among patients with KMT2A-rearranged acute leukemia in the phase 2 AUGMENT-101 study.
Advocacy groups such as Cancer Support Community and the Leukemia & Lymphoma Society may help support patients with CML undergoing treatment.
Related Content